In this podcast, we discuss explore the potential impact of President Trump's recent tariff announcements on the pharmaceutical and life sciences sectors, with a focus on the UK and US markets.
With rumors that tariffs could be as high as 200% 100% in some cases, global supply chains and pharmaceutical production face significant disruptions.
Our experts discuss the evolving landscape and offer valuable insights into of what businesses are having to consider both sides of the Atlantic how businesses are adapting to the changing trade environment.
Related tags
Yogan Patel
Head of Pharma and Life Sciences MHA
Andrew Thurston
Customs and Duty Manager at MHA
Darren Jones
Life Sciences Industry Leader at Baker Tilly US
Discover more insights
Insights
Kanika Mishra Pathak
Lead R&D Director
The Future of Fintech: Balancing Innovation, Regulation, and Customer Experience
Kanika Mishra Pathak
Lead R&D Director
Insights
The highs and lows of self-billing arrangements
Insights
Andrew Thurston
Customs Duty & Indirect Tax Consultant
President Trump's global tariffs and tariffs war update
Andrew Thurston
Customs Duty & Indirect Tax Consultant
Insights
Mark Lumsdon-Taylor
Partner
Shifting Sands: ESG rules paused, but business planning must continue
Mark Lumsdon-Taylor
Partner
Insights
Employment Related Securities: Annual Reporting
Related tags
You can email us at [email protected]